Rockwell Medical, Inc.(RMTI)Earnings, Financials & Key Ratios
RMTI•NASDAQ
$0.81
$32M mkt cap·Price updated May 6, 2026
AboutRockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home. Its target customers include medium and small sized dialysis chains and independent dialysis centers. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.Show more
- Revenue$101M+21.4%
- EBITDA$3M+153.3%
- Net Income-$480K+94.3%
- EPS (Diluted)-0.03+93.0%
- Gross Margin17.23%+65.5%
- EBITDA Margin2.75%+144.0%
- Operating Margin0.6%+107.5%
- Net Margin-0.47%+95.3%
- ROE-1.78%+96.3%
- ROIC1.62%+107.5%
- Debt/Equity0.42-34.2%
- Interest Coverage0.48+116.7%
RMTI Key Insights
Rockwell Medical, Inc. (RMTI) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 7/9
- ✓Strong 5Y sales CAGR of 10.6%
- ✓Trading at only 0.8x book value
- ✓Efficient asset utilization: 1.7x turnover
✗Weaknesses
- ✗Shares diluted 33.2% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
RMTI Price & Volume
Rockwell Medical, Inc. (RMTI) stock price & volume — 10-year historical chart
Loading chart...
RMTI Growth Metrics
Rockwell Medical, Inc. (RMTI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years6.48%
5 Years10.61%
3 Years17.9%
TTM-23.6%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-346.28%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-211.82%
Return on Capital
10 Years-45.8%
5 Years-40.55%
3 Years-26.17%
Last Year1.51%
RMTI Peer Comparison
Rockwell Medical, Inc. (RMTI) competitors in Therapy-focused branded biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 | |
 LXRX | 677.89M | 1.60 | -11.43 | 60.24% | -101.08% | -41.94% | 0.58 | |
 SUPN | 2.96B | 51.45 | -75.66 | 8.63% | -3.74% | -2.73% | 0.04 | |
 HALO | 7.81B | 66.35 | 25.92 | 37.55% | 22.69% | 6.49% | ||
 PRGO | 1.69B | 12.26 | -1.19 | -2.75% | -43.5% | -50.65% | 1.35 | |
 DVA | 12.79B | 193.88 | 20.39 | 6.46% | 5.65% | 59.11% | 12.99 | |
 FMC | 1.85B | 14.79 | -0.83 | -18.34% | -72.93% | -82.27% | 2.00 | |
 NXST | 5.98B | 197.21 | 65.74 | -8.47% | 2.2% |
Compare RMTI vs Peers
Rockwell Medical, Inc. (RMTI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RMTI Income Statement
Rockwell Medical, Inc. (RMTI) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 53.28M | 57.3M | 63.39M | 61.3M | 62.2M | 61.93M | 72.81M | 83.61M | 101.49M | 75.58M |
| Revenue Growth % | -3.73% | 7.54% | 10.63% | -3.29% | 1.46% | -0.43% | 17.57% | 14.84% | 21.38% | -23.6% |
| Cost of Goods Sold | 46.53M | 53.6M | 64.97M | 58.46M | 59.47M | 64.35M | 68.73M | 74.91M | 84M | 64.13M |
| COGS % of Revenue | 87.33% | 93.54% | 102.5% | 95.37% | 95.62% | 103.91% | 94.4% | 89.59% | 82.77% | - |
| Gross Profit | 6.75M▲ 0% | 3.7M▼ 45.2% | -1.58M▼ 142.8% | 2.84M▲ 279.2% | 2.73M▼ 4.0% | -2.42M▼ 188.8% | 4.08M▲ 268.5% | 8.7M▲ 113.5% | 17.48M▲ 100.9% | 11.45M▲ 0% |
| Gross Margin % | 12.67% | 6.46% | -2.5% | 4.63% | 4.38% | -3.91% | 5.6% | 10.41% | 17.23% | 15.15% |
| Gross Profit Growth % | -24.45% | -45.18% | -142.8% | 279.17% | -4.01% | -188.81% | 268.47% | 113.49% | 100.87% | - |
| Operating Expenses | 26.96M | 29.62M | 29.82M | 36.93M | 31.14M | 27.92M | 20.86M | 15.37M | 16.88M | 16.26M |
| OpEx % of Revenue | 50.6% | 51.7% | 47.05% | 60.25% | 50.07% | 45.08% | 28.65% | 18.39% | 16.63% | - |
| Selling, General & Admin | 21.12M | 23.3M | 23.08M | 30.05M | 24.05M | 21.08M | 17.74M | 14.27M | 16.86M | 16.26M |
| SG&A % of Revenue | 39.64% | 40.67% | 36.41% | 49.02% | 38.67% | 34.04% | 24.36% | 17.06% | 16.61% | - |
| Research & Development | 5.84M | 6.32M | 6.74M | 6.89M | 7.09M | 6.83M | 3.12M | 1.11M | 19K | 1K |
| R&D % of Revenue | 10.96% | 11.03% | 10.64% | 11.23% | 11.4% | 11.04% | 4.28% | 1.32% | 0.02% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -20.21M▲ 0% | -25.92M▼ 28.3% | -32.44M▼ 25.1% | -34.1M▼ 5.1% | -28.42M▲ 16.6% | -30.34M▼ 6.7% | -16.78M▲ 44.7% | -6.67M▲ 60.3% | 608K▲ 109.1% | -4.81M▲ 0% |
| Operating Margin % | -37.93% | -45.24% | -51.18% | -55.62% | -45.69% | -48.98% | -23.05% | -7.98% | 0.6% | -6.37% |
| Operating Income Growth % | -33.81% | -28.28% | -25.14% | -5.11% | 16.65% | -6.74% | 44.69% | 60.25% | 109.12% | - |
| EBITDA | -19.45M | -25.41M | -31.79M | -31.44M | -26.13M | -27.82M | -16.2M | -5.23M | 2.79M | -3.11M |
| EBITDA Margin % | -36.5% | -44.34% | -50.15% | -51.29% | -42.01% | -44.92% | -22.26% | -6.25% | 2.75% | -4.11% |
| EBITDA Growth % | -36.18% | -30.66% | -25.11% | 1.09% | 16.89% | -6.47% | 41.76% | 67.75% | 153.35% | -212.25% |
| D&A (Non-Cash Add-back) | 762.37K | 514.36K | 650.14K | 2.65M | 2.29M | 2.52M | 576K | 1.44M | 2.18M | 1.71M |
| EBIT | -19.4M | -25.92M | -31.41M | -34.1M | -29.01M | -30.31M | -16.74M | -6.14M | 774K | -4.39M |
| Net Interest Income | 810.34K | 790.23K | 535.64K | 367K | -1.64M | -2.34M | -1.9M | -2.09M | -1.16M | -908K |
| Interest Income | 810.34K | 790.23K | 535.33K | 367.08K | 238K | 22K | 33K | 211K | 92K | 219K |
| Interest Expense | 0 | 0 | 0 | 0 | 1.88M | 2.36M | 1.94M | 2.3M | 1.25M | 1.13M |
| Other Income/Expense | 810.34K | 1.63K | -716.7K | -3.08M | -2.47M | -2.34M | -1.9M | -1.77M | -1.09M | -704K |
| Pretax Income | -19.4M▲ 0% | -25.92M▼ 33.6% | -32.13M▼ 23.9% | -37.18M▼ 15.7% | -30.89M▲ 16.9% | -32.67M▼ 5.8% | -18.68M▲ 42.8% | -8.44M▲ 54.8% | -480K▲ 94.3% | -5.52M▲ 0% |
| Pretax Margin % | -36.41% | -45.24% | -50.68% | -60.65% | -49.66% | -52.76% | -25.65% | -10.09% | -0.47% | -7.3% |
| Income Tax | 404.53K | -1.63K | 313.3K | -3.05M | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | -2.09% | 0.01% | -0.98% | 8.2% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -19.8M▲ 0% | -25.92M▼ 30.9% | -32.13M▼ 23.9% | -34.13M▼ 6.2% | -30.89M▲ 9.5% | -32.67M▼ 5.8% | -18.68M▲ 42.8% | -8.44M▲ 54.8% | -480K▲ 94.3% | -5.52M▲ 0% |
| Net Margin % | -37.16% | -45.24% | -50.68% | -55.67% | -49.66% | -52.76% | -25.65% | -10.09% | -0.47% | -7.3% |
| Net Income Growth % | -37.33% | -30.9% | -23.94% | -6.23% | 9.49% | -5.78% | 42.83% | 54.82% | 94.31% | -346.28% |
| Net Income (Continuing) | -19.8M | -25.92M | -32.13M | -34.13M | -30.89M | -32.67M | -18.68M | -8.44M | -480K | -5.52M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -4.29▲ 0% | -5.61▼ 30.8% | -6.69▼ 19.3% | -5.61▲ 16.1% | -4.49▲ 20.0% | -3.83▲ 14.7% | -1.89▲ 50.7% | -0.36▲ 81.0% | -0.03▲ 93.0% | -0.15▲ 0% |
| EPS Growth % | -34.48% | -30.77% | -19.25% | 16.14% | 19.96% | 14.7% | 50.65% | 80.95% | 93% | -211.82% |
| EPS (Basic) | -4.30 | -5.61 | -6.69 | -5.61 | -4.49 | -3.83 | -1.89 | -0.36 | -0.03 | - |
| Diluted Shares Outstanding | 4.62M | 4.62M | 4.8M | 5.54M | 6.87M | 8.53M | 9.87M | 23.32M | 31.06M | 36.02M |
| Basic Shares Outstanding | 4.61M | 4.62M | 4.8M | 5.54M | 6.87M | 8.53M | 9.87M | 23.32M | 31.06M | 36.02M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
RMTI Balance Sheet
Rockwell Medical, Inc. (RMTI) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 78.51M | 48.83M | 46.83M | 36.87M | 69.47M | 35.29M | 35.31M | 28.77M | 37.03M | 37.51M |
| Cash & Short-Term Investments | 57.94M | 33.06M | 33.53M | 26.05M | 58.68M | 22.44M | 21.49M | 10.94M | 21.6M | 23.71M |
| Cash Only | 17.18M | 8.41M | 22.71M | 11.79M | 48.68M | 13.28M | 10.1M | 8.98M | 15.66M | 13.61M |
| Short-Term Investments | 40.76M | 24.65M | 10.82M | 14.25M | 10M | 9.16M | 11.39M | 1.95M | 5.94M | 10.1M |
| Accounts Receivable | 6.39M | 6.36M | 7.35M | 4.2M | 4.17M | 5.91M | 6.26M | 10.9M | 8.29M | 8.33M |
| Days Sales Outstanding | 43.79 | 40.48 | 42.33 | 25.02 | 24.48 | 34.85 | 31.38 | 47.59 | 29.82 | 41.5 |
| Inventory | 12.14M | 7.64M | 4.04M | 3.65M | 3.91M | 4.08M | 5.81M | 5.87M | 5.78M | 3.96M |
| Days Inventory Outstanding | 95.24 | 52.01 | 22.69 | 22.77 | 24.02 | 23.12 | 30.87 | 28.61 | 25.11 | 26.96 |
| Other Current Assets | 2.03M | 0 | 0 | 0 | 0 | 0 | 1.75M | 1.06M | 1.36M | 1.51M |
| Total Non-Current Assets | 4.64M | 9.95M | 5.73M | 7.44M | 8.28M | 13.29M | 11.32M | 23.4M | 22.18M | 19.97M |
| Property, Plant & Equipment | 1.39M | 2.55M | 2.64M | 5.65M | 5.55M | 10.22M | 8.61M | 11.02M | 10.34M | 8.7M |
| Fixed Asset Turnover | 38.29x | 22.48x | 24.03x | 10.86x | 11.20x | 6.06x | 8.46x | 7.59x | 9.81x | 7.94x |
| Goodwill | 920.75K | 920.75K | 920.75K | 921K | 921K | 921K | 921K | 921K | 921K | 921K |
| Intangible Assets | 4.38K | 4.03K | 0 | 0 | 0 | 0 | 0 | 10.76M | 10.21M | 9.79M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 2.33M | 6.48M | 2.17M | 876K | 1.8M | 2.14M | 1.8M | 705K | 706K | 2.35M |
| Total Assets | 83.15M▲ 0% | 58.78M▼ 29.3% | 52.56M▼ 10.6% | 44.32M▼ 15.7% | 77.75M▲ 75.4% | 48.57M▼ 37.5% | 46.63M▼ 4.0% | 52.17M▲ 11.9% | 59.21M▲ 13.5% | 57.49M▲ 0% |
| Asset Turnover | 0.64x | 0.97x | 1.21x | 1.38x | 0.80x | 1.27x | 1.56x | 1.60x | 1.71x | 1.35x |
| Asset Growth % | -5.32% | -29.31% | -10.59% | -15.68% | 75.44% | -37.52% | -3.99% | 11.88% | 13.48% | 19.81% |
| Total Current Liabilities | 10.15M | 9.14M | 13.2M | 12.37M | 12.79M | 20.97M | 17.69M | 16.64M | 14.09M | 9.58M |
| Accounts Payable | 5.86M | 4.22M | 4.49M | 3.02M | 4.16M | 3.74M | 4.05M | 4.52M | 2.87M | 1.52M |
| Days Payables Outstanding | 45.95 | 28.75 | 25.24 | 18.84 | 25.5 | 21.21 | 21.52 | 22 | 12.47 | 11.13 |
| Short-Term Debt | 0 | 0 | 0 | 763K | 0 | 7.82M | 2.13M | 244K | 268K | 462K |
| Deferred Revenue (Current) | 77.22K | 205.3K | 2.32M | 2.29M | 2.33M | 2.31M | 1.8M | 289K | 143K | 589K |
| Other Current Liabilities | 2M | 1.99M | 2.38M | 1.49M | 3.03M | 2.17M | 2.87M | 5.17M | 5.29M | 4.14M |
| Current Ratio | 7.74x | 5.34x | 3.55x | 2.98x | 5.43x | 1.68x | 2.00x | 1.73x | 2.63x | 2.63x |
| Quick Ratio | 6.54x | 4.51x | 3.24x | 2.69x | 5.12x | 1.49x | 1.67x | 1.38x | 2.22x | 2.22x |
| Cash Conversion Cycle | 93.08 | 63.74 | 39.78 | 28.95 | 22.99 | 36.76 | 40.73 | 54.19 | 42.46 | 57.34 |
| Total Non-Current Liabilities | 20.05M | 16.72M | 12.08M | 11.62M | 30.79M | 25.07M | 14.84M | 14.24M | 12.53M | 10.88M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 20.95M | 13.19M | 7.55M | 8.29M | 8.47M | 8.74M |
| Capital Lease Obligations | 0 | 0 | 0 | 1.78M | 1.82M | 5.89M | 4.67M | 2.96M | 2.63M | 9.57M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 14K | 14K | 2.51M | 1M | 1.5M |
| Total Liabilities | 30.2M | 25.87M | 25.28M | 24M | 43.58M | 46.04M | 32.53M | 30.88M | 26.62M | 20.47M |
| Total Debt | 0 | 0 | 0 | 4.04M | 23.94M | 28.89M | 16.36M | 13.44M | 13.54M | 13.13M |
| Net Debt | -17.18M | -8.41M | -22.71M | -7.76M | -24.75M | 15.62M | 6.26M | 4.46M | -2.13M | -485K |
| Debt / Equity | - | - | - | 0.20x | 0.70x | 11.40x | 1.16x | 0.63x | 0.42x | 0.42x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | 4.85x | -4.23x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | -0.76x | -0.76x |
| Interest Coverage | - | - | - | - | -15.13x | -12.85x | -8.67x | -2.90x | 0.48x | -3.89x |
| Total Equity | 52.96M▲ 0% | 32.91M▼ 37.8% | 27.28M▼ 17.1% | 20.32M▼ 25.5% | 34.17M▲ 68.2% | 2.54M▼ 92.6% | 14.11M▲ 456.4% | 21.29M▲ 50.9% | 32.59M▲ 53.1% | 37.02M▲ 0% |
| Equity Growth % | -15.02% | -37.85% | -17.12% | -25.5% | 68.16% | -92.58% | 456.45% | 50.94% | 53.05% | 162.23% |
| Book Value per Share | 11.47 | 7.12 | 5.68 | 3.67 | 4.97 | 0.30 | 1.43 | 0.91 | 1.05 | 1.03 |
| Total Shareholders' Equity | 52.96M | 32.91M | 27.28M | 20.32M | 34.17M | 2.54M | 14.11M | 21.29M | 32.59M | 37.02M |
| Common Stock | 268.2M | 273.21M | 5.7K | 7K | 9K | 1K | 1K | 3K | 3K | 4K |
| Retained Earnings | -214.34M | -240.26M | -272.39M | -306.52M | -337.41M | -370.08M | -388.76M | -397.2M | -397.68M | -402.44M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -902.55K | -35.38K | 63.15K | 52K | 57K | 52K | 163K | -1K | 54K | 73K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RMTI Cash Flow Statement
Rockwell Medical, Inc. (RMTI) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -12.45M | -21.11M | -20.42M | -27.25M | -29.64M | -33.53M | -16.93M | -9.41M | 4.2M | 4.2M |
| Operating CF Margin % | -23.37% | -36.85% | -32.21% | -44.46% | -47.66% | -54.15% | -23.25% | -11.26% | 4.14% | - |
| Operating CF Growth % | 23.33% | -69.56% | 3.29% | -33.47% | -8.76% | -13.13% | 49.52% | 44.4% | 144.65% | 1962.42% |
| Net Income | -19.8M | -25.92M | -32.13M | -34.13M | -30.89M | -32.67M | -18.68M | -8.44M | -480K | -5.52M |
| Depreciation & Amortization | 762.37K | 514.36K | 650.14K | 2.65M | 2.29M | 2.52M | 576K | 1.44M | 2.18M | 2.19M |
| Stock-Based Compensation | 10.35M | 7.17M | 4.39M | 4.95M | 475K | 943K | 315K | 932K | 1.29M | 1.21M |
| Deferred Taxes | -10.31M | 0 | 9M | 0 | 0 | 156K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 10.35M | 802.98K | 1.1M | 1.24M | 1.44M | 369K | 2.98M | 3.9M | 2.74M | 3.07M |
| Working Capital Changes | -3.79M | -3.68M | -3.43M | -1.98M | -2.96M | -4.84M | -2.13M | -7.24M | -1.53M | -3.04M |
| Change in Receivables | -1.16M | -962.34K | -623.95K | 2.78M | 32K | -1.74M | -346K | -4.64M | 2.61M | 549K |
| Change in Inventory | -6.1M | 343.49K | -835.64K | 316.87K | -1.31M | -656K | -2.1M | 1.18M | -332K | 1.87M |
| Change in Payables | 1.86M | -1.64M | 269.91K | -1.47M | 1.14M | -416K | 314K | 463K | -1.65M | -1.08M |
| Cash from Investing | -1.64M | 14.5M | 12.72M | -4.75M | 3.21M | 311K | -2.4M | -3.04M | -4.87M | -4.75M |
| Capital Expenditures | -355.26K | -1.68M | -994.26K | -1.34M | -1.05M | -522K | -281K | -284K | -1.01M | -851K |
| CapEx % of Revenue | 0.67% | 2.94% | 1.57% | 2.18% | 1.68% | 0.84% | 0.39% | 0.34% | 1% | - |
| Acquisitions | 1K | 725 | -250K | 750K | 0 | -833K | 0 | -12.36M | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 1K | 725 | 250.4K | -750K | 0 | 833K | 0 | 0 | 0 | 0 |
| Cash from Financing | 80.16K | -2.16M | 22M | 21.08M | 63.32M | -2.18M | 16.15M | 11.34M | 7.35M | 8.1M |
| Debt Issued (Net) | 0 | 0 | 0 | -1.15M | 21.74M | -2.28M | -13.68M | -3.51M | -1.2M | -1.23M |
| Equity Issued (Net) | 80.16K | 123.6K | 1000K | 1000K | 1000K | 107K | 1000K | 1000K | 1000K | 2M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | -2.29M | 0 | -279K | -19K | -6K | 0 | 0 | 0 | 0 |
| Other Financing | 0 | -2.29M | 3.5K | -1.65M | -3.88M | -6K | -191K | -5K | -1.63M | -2.27M |
| Net Change in Cash | -14.02M▲ 0% | -8.77M▲ 37.4% | 14.31M▲ 263.1% | -10.92M▼ 176.3% | 36.89M▲ 437.8% | -35.4M▼ 196.0% | -3.18M▲ 91.0% | -1.12M▲ 64.8% | 6.68M▲ 696.9% | 1.27M▲ 0% |
| Free Cash Flow | -12.81M▲ 0% | -22.8M▼ 78.0% | -21.41M▲ 6.1% | -28.59M▼ 33.5% | -30.69M▼ 7.3% | -34.06M▼ 11.0% | -17.21M▲ 49.5% | -9.7M▲ 43.7% | 3.19M▲ 132.9% | -2.94M▲ 0% |
| FCF Margin % | -24.04% | -39.79% | -33.78% | -46.64% | -49.34% | -54.99% | -23.64% | -11.6% | 3.14% | -3.88% |
| FCF Growth % | 24.91% | -77.99% | 6.07% | -33.52% | -7.33% | -10.98% | 49.47% | 43.66% | 132.91% | -211.42% |
| FCF per Share | -2.77 | -4.93 | -4.46 | -5.16 | -4.46 | -3.99 | -1.74 | -0.42 | 0.10 | 0.10 |
| FCF Conversion (FCF/Net Income) | 0.63x | 0.81x | 0.64x | 0.80x | 0.96x | 1.03x | 0.91x | 1.12x | -8.75x | 0.53x |
| Interest Paid | 0 | 0 | 0 | 0 | 1.56M | 0 | 1.47M | 1.21M | 847K | 582K |
| Taxes Paid | 404.53K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RMTI Key Ratios
Rockwell Medical, Inc. (RMTI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -34.36% | -60.37% | -106.75% | -143.4% | -113.38% | -178.04% | -224.49% | -47.68% | -1.78% | -14.9% |
| Return on Invested Capital (ROIC) | -45.31% | -64.5% | -167.39% | -298.65% | -193.89% | -165.02% | -65.35% | -21.7% | 1.62% | 1.62% |
| Gross Margin | 12.67% | 6.46% | -2.5% | 4.63% | 4.38% | -3.91% | 5.6% | 10.41% | 17.23% | 15.15% |
| Net Margin | -37.16% | -45.24% | -50.68% | -55.67% | -49.66% | -52.76% | -25.65% | -10.09% | -0.47% | -7.3% |
| Debt / Equity | - | - | - | 0.20x | 0.70x | 11.40x | 1.16x | 0.63x | 0.42x | 0.42x |
| Interest Coverage | - | - | - | - | -15.13x | -12.85x | -8.67x | -2.90x | 0.48x | -3.89x |
| FCF Conversion | 0.63x | 0.81x | 0.64x | 0.80x | 0.96x | 1.03x | 0.91x | 1.12x | -8.75x | 0.53x |
| Revenue Growth | -3.73% | 7.54% | 10.63% | -3.29% | 1.46% | -0.43% | 17.57% | 14.84% | 21.38% | -23.6% |
RMTI Frequently Asked Questions
Rockwell Medical, Inc. (RMTI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Rockwell Medical, Inc. (RMTI) reported $75.6M in revenue for fiscal year 2024. This represents a 2190% increase from $3.3M in 1997.
Rockwell Medical, Inc. (RMTI) grew revenue by 21.4% over the past year. This is strong growth.
Rockwell Medical, Inc. (RMTI) reported a net loss of $5.5M for fiscal year 2024.
Dividend & Returns
Rockwell Medical, Inc. (RMTI) has a return on equity (ROE) of -1.8%. Negative ROE indicates the company is unprofitable.
Rockwell Medical, Inc. (RMTI) had negative free cash flow of $2.9M in fiscal year 2024, likely due to heavy capital investments.
Explore More RMTI
Rockwell Medical, Inc. (RMTI) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates